Duojia Pan

USPTO Granted Patents = 11 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 64(Granted Patents)

Location History:

Berkeley, CA (US) (1999 - 2002)
Dallas, TX (US) (2002 - 2022)
Baltimore, MD (US) (2009 - 2022)

Company Filing History:

5 out of 15,475

University of California

patents

3 out of 3,687

Johns Hopkins University

The University of Texas System

patents

5. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312398 - Compositions and methods for targeting activin signaling to treat cancer (2025-05-27),

2. 11491139 - Inhibition of YAP for breaking tumor immune tolerance (2022-11-08),

3. 11236156 - Compositions and methods for targeting activin signaling to treat cancer (2022-02-01),

4. 7556942 - Tumor suppressor designated Hippo (2009-07-07),

5. 7537759 - Modulating angiogenesis (2009-05-26),

6. 6872750 - Modulating angiogenesis (2005-03-29),

7. 6436629 - Modulating angiogenesis (2002-08-20),

8. 6399350 - KUZ, a novel family of metalloproteases (2002-06-04),

9. 6319704 - KUZ, a novel family of metalloproteases (2001-11-20),

10. 6190876 - KUZ, a novel family of metalloproteases (2001-02-20),

11. 5935792 - KUZ, a novel family of metalloproteases (1999-08-10),

Title: Duojia Pan: Innovator in Cancer Therapeutics

Introduction

Duojia Pan is a prominent inventor based in Dallas, TX, known for his significant contributions to the field of cancer research. With a remarkable portfolio of 11 patents, he has dedicated his career to developing innovative treatments aimed at targeting the underlying mechanisms of cancer.

Latest Patents

Duojia Pan's recent patents encompass critical advancements in cancer therapeutics. One notable invention is a method for targeting the Activin signaling pathway to treat cancer. This invention proposes using compositions that inhibit Activin signaling and combine it with immunomodulation to modify Treg cell-mediated immune regulation, ultimately aiding in cancer treatment. Another pivotal patent focuses on the inhibition of the Yes-associated protein (YAP) as a means to disrupt tumor immune tolerance. YAP, a key regulator in Treg cells, plays an essential role in maintaining their suppressive activity. The patent highlights that targeting YAP can enhance anti-tumor immune responses, making it a vital immunotherapeutic target.

Career Highlights

Duojia Pan's career includes positions at prestigious institutions such as the University of California and The Johns Hopkins University. His extensive research and expertise have positioned him as a leading figure in cancer therapy innovation, contributing to advancements that have the potential to change the landscape of cancer treatment.

Collaborations

Throughout his career, Duojia Pan has collaborated with esteemed colleagues, including Gerald M. Rubin and Jenny Rooke. These collaborations reflect his commitment to fostering teamwork in developing groundbreaking solutions to complex medical challenges.

Conclusion

With his ground-breaking patents and collaborations, Duojia Pan continues to push the boundaries of cancer research. His work not only showcases his innovative spirit but also highlights the critical need for advancements in cancer therapeutics, ultimately striving towards improved outcomes for patients battling this formidable disease.

This text is generated by artificial intelligence and may not be accurate.